EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C Issa iD, Branko Cuglievan iD, Georgina El Hajjar iD, Wei Ying Jen iD, Alex Bataller iD, Nicholas J Short, Courtney D DiNardo iD, Yesid Alvarado iD, Sanam Loghavi iD, Dzifa Yawa Duose, Baili Zhang, Ken Furudate iD und 20 weitere

Journal of Clinical Oncology · 01.08.2026 · 44 (22) · 2110-2120

DOI: 10.1200/jco-26-01159 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.08.2026. Verfasst von Ghayas C Issa und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Revumenib is an oral inhibitor of menin-KMT2A, a key dependency in acute myeloid leukemia (AML) with KMT2A rearrangement ( KMT2Ar ), NPM1 mutation ( NPM1mt ), or NUP98 rearrangement ( NUP98r ). Preclinical studies suggest synergy with BCL2 inhibition. METHODS In this phase I-II study, we evaluated an all-oral regimen of revumenib, decitabine/cedazuridine, and venetoclax in patients 12 years and older with relapsed or refractory AML. Decitabine/cedazuridine was given on days 1-5, venetoclax on days 1-14, and revumenib twice daily on days 1-28. The primary objectives were to determine the recommended phase II dose (RP2D) and to assess efficacy according to the composite complete remission (CRc) rate. RESULTS Forty-two patients were enrolled (median age, 40 years; range, 12-82) including 40% with KMT2Ar, 38% with NPM1mt , and 21% with NUP98r. Patients had a median of two prior lines of therapy; 52% had prior venetoclax. The RP2D of revumenib was 160 mg twice daily with a strong CYP3A4 inhibitor. Grade ≥3 adverse events included febrile neutropenia (36%), lung infection (21%), and thrombocytopenia (21%). Differentiation syndrome occurred in 10% (5% grade 3) and resolved with glucocorticoids. The CRc rate was 71%, and the CR or complete remission with partial hematologic recovery (CR/CRh) rate was 60%, with measurable residual disease negativity by flow cytometry in 80% of these patients. The median duration of CR/CRh for all patients was 10.5 months, not reached in KMT2Ar , 10.7 months in NPM1mt , and 5.9 months in NUP98r . Emergent mutations in the menin-binding site occurred in 13%. CONCLUSION This combination was associated with high response rates and durable remissions, with an acceptable safety, in heavily pretreated patients with AML harboring alterations susceptible to menin inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsHumansBridged Bicyclo Compounds, HeterocyclicNucleophosminSulfonamidesChildFemaleAdolescentAdultMiddle AgedDecitabineMaleAged, 80 and overAgedYoung AdultAdministration, OralRemission InductionRecurrenceBenzamidesSpiro Compounds

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicNucleophosminSulfonamidesNPM1 protein, humanDecitabinerevumenibBenzamidesSpiro Compounds

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Housto, TX.
  • Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, Wei Ying Jen, Alex Bataller, Courtney D DiNardo, Yesid Alvarado, Sanam Loghavi, Ken Furudate, Jing Ning, Elie Mouhayar, Naval Daver, Guillermo Garcia-Manero, David McCall, Tapan M Kadia, Hussein A Abbas, Alexandre Bazinet, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Michael Andreeff, Hagop M Kantarjian

Förderung

  • NCI NIH HHS

Zitieren

APA

Issa, G. C., Cuglievan, B., El Hajjar, G., Jen, W. Y., Bataller, A., Short, N. J., DiNardo, C. D., Alvarado, Y., Loghavi, S., Duose, D. Y., Zhang, B., Furudate, K., Ning, J., Xiao, L., Mouhayar, E., Pinto, A., Bidikian, A., Thompson, E., Daver, N., …, & Kantarjian, H. M. (2026). All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). Journal of Clinical Oncology, 44(22), 2110-2120. https://doi.org/10.1200/jco-26-01159

Vancouver

Issa GC, Cuglievan B, El Hajjar G, Jen WY, Bataller A, Short NJ, et al. All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). Journal of Clinical Oncology. 2026;44(22):2110-2120. doi:10.1200/jco-26-01159

BibTeX
@article{Issa2026,
  author = {Issa, Ghayas C and Cuglievan, Branko and El Hajjar, Georgina and Jen, Wei Ying and Bataller, Alex and Short, Nicholas J and DiNardo, Courtney D and Alvarado, Yesid and Loghavi, Sanam and Duose, Dzifa Yawa and Zhang, Baili and Furudate, Ken and Ning, Jing and Xiao, Lianchun and Mouhayar, Elie and Pinto, Alessandro and Bidikian, Aram and Thompson, Erika and Daver, Naval and Garcia-Manero, Guillermo and Farhat, Aziz and McCall, David and Kadia, Tapan M and Abbas, Hussein A and Tan, Sheila and Bazinet, Alexandre and Jabbour, Elias and Montalban-Bravo, Guillermo and Ravandi, Farhad and Takahashi, Koichi and Andreeff, Michael and Kantarjian, Hagop M},
  title = {All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {22},
  pages = {2110--2120},
  doi = {10.1200/jco-26-01159}
}
Kostenlos starten →